Argenx Se (ARGX) Stock Forecast & Price Target

Compare

693 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARGX Analyst Ratings

Strong Buy

21 Buy

2 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Argenx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARGX Stock 12 Month Forecast

Average Price Target

$875.11

▲(7.07% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Argenx Se in the last 3 months. The average price target is $875.11 with a high forecast of $1,070.00 and a low forecast of $710.00. The average price target represents a 7.07% change from the last price of $817.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"541":"$541","806":"$806","1071":"$1,071","673.5":"$673.5","938.5":"$938.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1070,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.07K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":875.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$875.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$710.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[541,673.5,806,938.5,1071],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,767.33,790.6123076923077,813.8946153846155,837.1769230769231,860.4592307692308,883.7415384615385,907.0238461538462,930.3061538461538,953.5884615384616,976.8707692307693,1000.1530769230769,1023.4353846153847,1046.7176923076922,{"y":1070,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,767.33,775.6207692307693,783.9115384615385,792.2023076923077,800.493076923077,808.7838461538462,817.0746153846154,825.3653846153846,833.6561538461539,841.9469230769231,850.2376923076923,858.5284615384616,866.8192307692308,{"y":875.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,767.33,762.9200000000001,758.51,754.1,749.69,745.28,740.87,736.46,732.0500000000001,727.64,723.23,718.82,714.41,{"y":710,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":547.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":595.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":617.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":615,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":655.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":624.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":542.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":673.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":706.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":767.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,070

Average Price Target$875.11

Lowest Price Target$710.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha Semenkow

Citi

$845→$1,041

Buy

27.37%

Upside

Reiterated

10/22/25

Argenx Se (ARGX) Receives a Buy from Citi

Tazeen Ahmad

Bank of America Securities

$887→$942

Buy

15.25%

Upside

Reiterated

10/20/25

Argenx's Vyvgart: Strong Performance and Growth Potential Drive Buy RatingWe expect continued growth in generalized myasthenia gravis (gMG; rare neuromuscular disease) driven by geographic expansion, label expansion into seronegative patients— supported by ocular MG data expected in 1H26, and the recent approval of the prefilled syringe (PFS). In chronic inflammatory demyelinating polyneuropathy (CIDP; rare neuromuscular disease), management reported ~2,500 patients on Vyvgart at the end of 2Q, and we expect this number to rise as switch rates and first-line use expand, consistent with our CIDP survey results (see below). We remain bullish on Vyvgart’s commercial opportunity, with multiple avenues for growth, and view 3Q as a key milestone as the company approaches >$1bn in quarterly revenue. ARGX remains a 2025 top pick with a Buy rating and new $942/€807 PO (prev. $887/€757; see model changes inside).

Yaron Werber

TD Cowen

$800

Buy

-2.12%

Downside

Reiterated

10/15/25

TD Cowen Remains a Buy on Argenx Se (ARGX)

Derek Archila

Wells Fargo

$756→$1,057

Buy

29.33%

Upside

Reiterated

10/15/25

Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT), Argenx Se (NASDAQ: ARGX) and AnaptysBio (NASDAQ: ANAB)

David Nierengarten

Wedbush

$800→$880

Buy

7.67%

Upside

Reiterated

10/13/25

Argenx price target raised to $880 from $800 at WedbushArgenx price target raised to $880 from $800 at Wedbush

Gavin Clark-Gartner

Evercore ISI

$775

Buy

-5.18%

Downside

Reiterated

10/13/25

Argenx Se (ARGX) Gets a Buy from Evercore ISI

Luca Issi

RBC Capital

―

Buy

―

Reiterated

10/08/25

RBC Capital Remains a Buy on Argenx Se (ARGX)

Richard Felton

Goldman Sachs

$903→$916

Buy

12.07%

Upside

Reiterated

10/02/25

Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX)

Sean Laaman

Morgan Stanley

$766→$1,040

Buy

27.25%

Upside

Reiterated

09/30/25

Argenx Se (ARGX) Gets a Buy from Morgan Stanley

Alex Thompson CFA

Stifel Nicolaus

$797→$882

Buy

7.91%

Upside

Reiterated

09/18/25

Argenx price target raised to $882 from $797 at StifelArgenx price target raised to $882 from $797 at Stifel

Leland Gershell

Oppenheimer

―

Buy

―

Reiterated

09/18/25

Argenx Se (ARGX) Gets a Buy from Oppenheimer

Thomas Smith

Leerink Partners

$780

Buy

-4.57%

Downside

Reiterated

09/17/25

Argenx Se (ARGX) Receives a Rating Update from a Top Analyst

Myles Minter

William Blair

―

Buy

―

Reiterated

09/17/25

Argenx's Strategic Diversification and Promising Pipeline Highlighted by Buy Rating

Douglas Tsao

H.C. Wainwright

$774

Buy

-5.30%

Downside

Reiterated

09/17/25

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)

Yatin Suneja

Guggenheim

$1,070

Buy

30.92%

Upside

Reiterated

09/17/25

Guggenheim Remains a Buy on Argenx Se (ARGX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha Semenkow

Citi

$845→$1,041

Buy

27.37%

Upside

Reiterated

10/22/25

Argenx Se (ARGX) Receives a Buy from Citi

Tazeen Ahmad

Bank of America Securities

$887→$942

Buy

15.25%

Upside

Reiterated

10/20/25

Yaron Werber

TD Cowen

$800

Buy

-2.12%

Downside

Reiterated

10/15/25

TD Cowen Remains a Buy on Argenx Se (ARGX)

Derek Archila

Wells Fargo

$756→$1,057

Buy

29.33%

Upside

Reiterated

10/15/25

Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT), Argenx Se (NASDAQ: ARGX) and AnaptysBio (NASDAQ: ANAB)

David Nierengarten

Wedbush

$800→$880

Buy

7.67%

Upside

Reiterated

10/13/25

Argenx price target raised to $880 from $800 at WedbushArgenx price target raised to $880 from $800 at Wedbush

Gavin Clark-Gartner

Evercore ISI

$775

Buy

-5.18%

Downside

Reiterated

10/13/25

Argenx Se (ARGX) Gets a Buy from Evercore ISI

Luca Issi

RBC Capital

―

Buy

―

Reiterated

10/08/25

RBC Capital Remains a Buy on Argenx Se (ARGX)

Richard Felton

Goldman Sachs

$903→$916

Buy

12.07%

Upside

Reiterated

10/02/25

Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX)

Sean Laaman

Morgan Stanley

$766→$1,040

Buy

27.25%

Upside

Reiterated

09/30/25

Argenx Se (ARGX) Gets a Buy from Morgan Stanley

Alex Thompson CFA

Stifel Nicolaus

$797→$882

Buy

7.91%

Upside

Reiterated

09/18/25

Argenx price target raised to $882 from $797 at StifelArgenx price target raised to $882 from $797 at Stifel

Leland Gershell

Oppenheimer

―

Buy

―

Reiterated

09/18/25

Argenx Se (ARGX) Gets a Buy from Oppenheimer

Thomas Smith

Leerink Partners

$780

Buy

-4.57%

Downside

Reiterated

09/17/25

Argenx Se (ARGX) Receives a Rating Update from a Top Analyst

Myles Minter

William Blair

―

Buy

―

Reiterated

09/17/25

Argenx's Strategic Diversification and Promising Pipeline Highlighted by Buy Rating

Douglas Tsao

H.C. Wainwright

$774

Buy

-5.30%

Downside

Reiterated

09/17/25

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)

Yatin Suneja

Guggenheim

$1,070

Buy

30.92%

Upside

Reiterated

09/17/25

Guggenheim Remains a Buy on Argenx Se (ARGX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Argenx Se

1 Month

xxx

Success Rate

14/19 ratings generated profit

Average Return

+6.95%

initiated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.68% of your transactions generating a profit, with an average return of +6.95% per trade.

3 Months

xxx

Success Rate

25/34 ratings generated profit

Average Return

+16.38%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +16.38% per trade.

1 Year

Allison BratzelPiper Sandler

Success Rate

22/23 ratings generated profit

Average Return

+32.10%

reiterated a buy rating 2 months ago

Copying Allison Bratzel's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +32.10% per trade.

2 Years

xxx

Success Rate

34/34 ratings generated profit

Average Return

+86.64%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARGX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARGX has received 41 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ARGX average Analyst price target in the past 3 months is 875.11.

Each month's total comprises the sum of three months' worth of ratings.

ARGX Financial Forecast

ARGX Earnings Forecast

Next quarter’s earnings estimate for ARGX is $4.49 with a range of $2.94 to $6.49. The previous quarter’s EPS was $3.74. ARGX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ARGX has Preformed in-line its overall industry.

ARGX Sales Forecast

Next quarter’s sales forecast for ARGX is $1.07B with a range of $976.64M to $1.15B. The previous quarter’s sales results were $1.75B. ARGX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ARGX has Preformed in-line its overall industry.

ARGX Stock Forecast FAQ

What is ARGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Argenx Se’s 12-month average price target is 875.11.

What is ARGX’s upside potential, based on the analysts’ average price target?

Argenx Se has 7.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARGX a Buy, Sell or Hold?

Argenx Se has a consensus rating of Strong Buy which is based on 21 buy ratings, 2 hold ratings and 0 sell ratings.

What is Argenx Se’s price target?

The average price target for Argenx Se is 875.11. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,070.00 ,the lowest forecast is $710.00. The average price target represents 7.07% Increase from the current price of $817.32.

What do analysts say about Argenx Se?

Argenx Se’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of ARGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Argenx Se (ARGX) Stock Forecast & Price Target

ARGX Analyst Ratings

ARGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Argenx Se

ARGX Analyst Recommendation Trends

ARGX Financial Forecast

ARGX Earnings Forecast

ARGX Sales Forecast

ARGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts